Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

321 works between 1997 and 2025

221 - 240 of 321 works

2011

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

2011

Journal Article

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Coiffier, Bertrand, Osmanov, Evgenii A., Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A., Zinzani, Pier Luigi, LYM-3001 study investigators and Mollee, Peter (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12 (8), 773-84. doi: 10.1016/S1470-2045(11)70150-4

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

2011

Journal Article

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

Mollee, P., Jones, M., Stackelroth, J., van Kuilenburg, R., Joubert, W., Faoagali, J., Looke, D., Harper, J. and Clements, A. (2011). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. Journal of Hospital Infection, 78 (1), 26-30. doi: 10.1016/j.jhin.2011.01.018

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

2011

Journal Article

Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia

Weston, H., Cowell, V., Grimmett, K., Saal, R., Jones, M., Mills, T., Gill, D., Marlton, P., Bird, R. and Mollee, P. (2011). Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. Internal Medicine Journal, 41 (5), 408-415. doi: 10.1111/j.1445-5994.2010.02334.x

Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia

2011

Conference Publication

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

Morel-Kopp, MC, Tan, CW, Brighton, T, McRae, S, Tran, H, Mollee, P, Kershaw, G, Joseph, J, Coyle, L and Ward, C (2011). Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study. Unknown, unknown, unknown. HOBOKEN: WILEY-BLACKWELL.

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

2011

Conference Publication

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S. (2011). A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego, CA, United States, Dec 10-13, 2011. Washington, DC, United States: American Society of Hematology.

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

2011

Conference Publication

Analytical aspects of standardised protein electrophoresis and immunofixation reporting

Tate, Jill, for the Working Party on Standardised Reporting of Protein Electrophoresis, Mollee, Peter, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard and Wienholt, Louise (2011). Analytical aspects of standardised protein electrophoresis and immunofixation reporting. 35th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Sydney, NSW Australia, 4-6 June 2010. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0031-3025(16)33167-1

Analytical aspects of standardised protein electrophoresis and immunofixation reporting

2011

Journal Article

Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population

Keane, Colm, Mollee, Peter, Marlton, Paula and Gill, Devinder (2011). Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Annals of Hematology, 90 (3), 359-360. doi: 10.1007/s00277-010-1023-0

Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population

2011

Conference Publication

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

Tate, J., Mollee, P., Caldwell, G., Daly, J., Gillis, D., Jenkins, M., Jovanovich, S., Martin, H., Steele, R., Wienholt, L. and AACB Working Party Standardised Reporting of Protein Electrophoresis (2011). Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand. EuroMedLab Berlin 2011, Berlin, Germany, 15-19 May 2011. Berlin, Germany: Walter De Gruyter. doi: 10.1515/CCLM.2011.527

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

2011

Journal Article

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population

Morris, Kirk, Weston, Helen, Mollee, Peter, Marlton, Paula, Gill, Devinder and Kennedy, Glen (2011). Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population. Leukemia and Lymphoma, 52 (1), 85-91. doi: 10.3109/10428194.2010.532889

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2011

Journal Article

Proteomics in molecular diagnosis: typing of amyloidosis

Loo, Dorothy, Mollee, Peter N., Renaut, Patricia and Hill, Michelle M. (2011). Proteomics in molecular diagnosis: typing of amyloidosis. Journal of Biomedicine and Biotechnology, 2011 (1) 754109, 754109.1-754109.9. doi: 10.1155/2011/754109

Proteomics in molecular diagnosis: typing of amyloidosis

2010

Conference Publication

WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation

Gray, James X., McMillen, Lyle, Saal, Russell, Lane, Steven, Bird, Robert, Gill, Devinder, Mollee, Peter and Marlton, Paula (2010). WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation. Royal College of Pathologists of Australasia Pathology Update, Melbourne, VIC Australia, 26-28 February 2010. Oxford, United Kingdom: Elsevier. doi: 10.1097/01268031-201042001-00118

WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation

2010

Conference Publication

Survival and prognostic factors amongst Australian patients with AL amyloidosis

Mollee, P, Tate, J, Morris, K, Wellwood, J, Browne, M, Marlton, P, Bird, R, Mills, AK, Wood, P, Mapp, S and Gill, D (2010). Survival and prognostic factors amongst Australian patients with AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome Italy, Apr 18-21, 2010. LONDON: INFORMA HEALTHCARE.

Survival and prognostic factors amongst Australian patients with AL amyloidosis

2010

Conference Publication

Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis

Mollee, P., Tate, J., Weiss, D. and Solomon, A. (2010). Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome, Italy, 18-21, April 2010. London, United Kingdom: Informa Healthcare.

Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis

2010

Book Chapter

Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphoma

Kuruvilla, J., Mollee, P. and Lipton, J. H. (2010). Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphoma. Allogeneic stem cell transplantation. (pp. 89-108) edited by Lazarus, HM and Laughlin, MJ. Totowa, NJ, United States: Humana Press. doi: 10.1007/978-1-59745-478-0_7

Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphoma

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. 51st ASH Annual Meeting, New Orleans, LA United States, 5–8 December 2009. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v114.22.1382.1382

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

2009

Conference Publication

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

Gray, James X, McMillen, Lyle, Saal, Russell, Lane, Steven, Mollee, Peter, Bird, Robert, Gill, Devinder and Marlton, Paula (2009). WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML). 51st ASH Annual Meeting, New Orleans, LA, 5-8 December 2009. American Society of Hematology. doi: 10.1182/blood.v114.22.2639.2639

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

2009

Journal Article

Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States

Marshall, George, Tate, Jill and Mollee, P. (2009). Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States. American Journal of Clinical Pathology, 132 (2), 309-309. doi: 10.1309/AJCP8VOT5TVLAQBQ

Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States

2009

Journal Article

Quantitative serum free light chain assay: Analytical issues

Tate, Jill, Bazeley, Sheree, Sykes, Stephen and Mollee, Peter (2009). Quantitative serum free light chain assay: Analytical issues. Clinical Biochemist Reviews, 30 (3), 131-140.

Quantitative serum free light chain assay: Analytical issues

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au